Navigation Links
Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
Date:1/30/2008

BONITA SPRINGS, Fla., Jan. 30 /PRNewswire/ -- Tigris Pharmaceuticals, Inc., a privately held drug development company, has initiated a multi-center, Phase I, ascending dose clinical study of aminoflavone pro-drug (AFP-464) for the treatment of cancer. The first patient was dosed in December 2007 and enrollment is ongoing.

The primary objectives of the study are to determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of AFP-464 in patients with advanced solid tumors. The trial is expected to enroll up to approximately 35 patients across two sites in Europe: Institut Gustave-Roussy, Villejuif, France and Jules Bordet Institute, Brussels, Belgium. Results from the trial are expected to be available in early 2009.

"We are delighted that dosing has begun in this important dose-escalation study of AFP-464 in patients with solid tumors," said Edmundo Muniz, Chief Executive Officer of Tigris. "AFP-464 is a first-in-class molecule with the potential to fill a large unmet medical need in the treatment of cancer. This first trial in Europe along with the two US Phase 1 trials provides us our first opportunity to assess the drug's activity in patients, and to further build on our understanding of the molecule's mechanism of action."

About AFP-464

AFP-464 is a novel anticancer agent currently being investigated in two phase 1 clinical trials sponsored by the National Cancer Institute ("NCI") in patients with solid tumors. Preclinical studies into AFP-464's mechanism of action have shown that AFP-464 is converted to metabolites which bind covalently to DNA, resulting in p53 activation and apoptosis. AFP-464 has shown a unique pattern of growth inhibitory activity in the NCI's 60 tumor cell line screen, with breast, ovarian, lung and renal tumor cell lines exhibiting particular sensitivity to the compound. In vivo antitumor activity of AFP-464 has been demonstrated in several xenograft studies in mice bearing renal and brea
'/>"/>

SOURCE Tigris Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
2. Poniard Pharmaceuticals Announces Picoplatin Safety Data in Colorectal Cancer
3. Peregrine Pharmaceuticals Receives Approval to Conduct a Second Phase II Trial of Bavituximab in Patients With Advanced Breast Cancer
4. Peregrine Pharmaceuticals Receives Approval to Conduct a Phase II Trial of Bavituximab in Patients With Non-Small Cell Lung Cancer
5. Cogentus Pharmaceuticals Begins Clinical Study to Confirm the Full Antiplatelet Benefit of New Combination Medicine CGT-2168
6. Cerimon Pharmaceuticals Initiates Phase II/III Clinical Studies to Evaluate its Diclofenac Patch for Mild to Moderate Pain
7. Morria Biopharmaceuticals Plc Announces Preliminary Safety and Tolerability Results From Its Phase I Clinical Study of MRX-4 in Allergic Rhinitis Patients
8. First Patient Enrolled in Cogentus Pharmaceuticals Pivotal Phase 3 Trial of Novel Combination Medicine
9. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
10. Vion Pharmaceuticals Announces FDA Lift of Clinical Hold on Phase III Study of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed AML
11. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 31, 2014  Zebra Imaging, Inc., the world,s ... today a strategic partnership with the Zygote Media ... anatomy and biomedical models for animation and visual ... markets.  Zygote maintains the world,s most comprehensive library ... has pioneered development of high-end solid 3D anatomy ...
(Date:10/31/2014)...  Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is ... in combination with gemcitabine, will be reimbursed via the ... cancer from 1 November. In ... th most common cause of cancer mortality. Pancreatic ... the lowest 5-year survival of all common cancers at ...
(Date:10/31/2014)... 31, 2014 Oramed Pharmaceuticals ... company focused on the development of oral drug ... a conference call to discuss the clinical results ... the company,s proprietary oral insulin capsules, to treat ... at 10:00 a.m. Eastern time. Shareholders ...
Breaking Medicine Technology:Zebra Imaging and Zygote Media Partner to Bring 3D Visualization to the Medical Community 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 2Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 3Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 4Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 5Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 6Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 7Specialised Therapeutics Australia Announces Breakthrough Cancer Drug Abraxane(R) to be PBS Listed for Metastatic Pancreatic Cancer 8Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 2Oramed to Report Key Top Line Results from U.S. Phase IIa Trial with Oral Insulin in Type 1 Diabetes 3
... SAN DIEGO, Nov. 28, 2011 OncoSec Medical ... advanced-stage OMS ElectroOncology therapies to treat skin cancer ... Punit Dhillon, President and CEO, will be presenting ... Conference in New York City. (Logo: ...
... 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: SHP ... and biotechnology research and development outsourcing company, today announced ... investor conferences in December 2011: Ms. Lan ... ShangPharma, will present at the following conferences: ...
Cached Medicine Technology:OncoSec to Present at 15th Annual Biotech and Specialty Pharmaceuticals Conference 2ShangPharma to Attend Two Upcoming Investor Conferences 2
(Date:10/31/2014)... Chico, CA. (PRWEB) October 31, 2014 ... best known for its small scale BioPro™ biodiesel ... equipment that will further improve the performance and ... , The GL95/MC12/BD380 trio will recover ... is mixed in with the glycerin by-product produced ...
(Date:10/31/2014)... Denver, Colorado (PRWEB) October 31, 2014 Daily ... new method is actually described as the fastest fat loss ... results in less than a month. , There is no ... fat loss eBook of all time. The new nutrition and ... popular nutrition and fitness expert. , According to the ...
(Date:10/31/2014)... (PRWEB) October 31, 2014 Activz ... Activz Silver line offering natural silver healing ... For over a century, silver has been used to ... Activz Silver products is the most advanced version available. ... a unique chemical structure that supports the existing healing ...
(Date:10/31/2014)... duration of treatment and cost, patients with early ... breast irradiation (APBI) with proton therapy versus whole ... The University of Texas MD Anderson Proton Therapy ... study based on typical patient characteristics, researchers used ... eight different types of partial and whole breast ...
(Date:10/31/2014)... 31, 2014 The Suspension Revolution review ... program was developed by Dan Long, a suspension training ... a fitness professional and life coach. The author of ... toned muscles is not impossible , The Suspension Revolution ... training. Suspension training promises efficiency when it comes to ...
Breaking Medicine News(10 mins):Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 2Health News:Springboard Biodiesel Announces Release of New and Unique Methanol Recovery and Glycerin Treatment Equipment 3Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 2Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 3Health News:New Collection of Nano-particle Natural Silver Products by Activz Whole-Food Nutrition 4Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 2Health News:Proton therapy shown to be less costly than some alternative radiotherapy techniques 3Health News:Suspension Revolution Review Reveals Dan Long's New Suspension Workout Plan 2
... Reporter , TUESDAY, April 19 (HealthDay News) -- The first ... disease could double the number of Americans defined as having ... Alzheimer,s Association and the U.S. National Institute of Aging, differ ... been in use since 1984. First, Alzheimer,s is ...
... , TUESDAY, April 19 (HealthDay News) -- Minority ... more likely to die in early childhood than whites, a ... nearly 20,000 black, Hispanic and white infants born with congenital ... Overall, black infants were 32 percent more likely to die ...
... . FRANKFURT, Germany. It is a rare ... start experiencing vision impairments, which two to three years ... indication of a progressive destruction of brain cells. Later ... finally, failure of all motor abilities. In this last ...
... at the University of California, San Diego School of ... found in people may be useful as a future ... early and, in sufficient concentration, used as a treatment ... led by Richard Schwab, MD, assistant clinical professor of ...
... HealthDay Reporter , TUESDAY, April 19 (HealthDay News) -- About ... were going to get all of the recommended vaccinations, and ... immunizations, two new surveys find. Pediatricians and infectious disease ... about a supposed autism/MMR (measles, mumps, rubella) link -- ...
... 2011, Springer will publish Translational Behavioral Medicine: ... the Society of Behavioral Medicine. The journal will ... Evidence Implementation. Translational Behavioral Medicine ... online-first publication. Its aim is to engage, ...
Cached Medicine News:Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 2Health News: Alzheimer's Cases Could Double With New Guidelines: Expert 3Health News:Minority Kids With Heart Defects More Likely to Die in Childhood 2Health News:Hope for children with rare genetic defect 2Health News:Hope for children with rare genetic defect 3Health News:A cancer marker and treatment in 1? 2Health News:A cancer marker and treatment in 1? 3Health News:Most Parents Vaccinate Kids, Trust Docs' Advice on Shots 2Health News:Most Parents Vaccinate Kids, Trust Docs' Advice on Shots 3Health News:Springer launches new journal, Translational Behavioral Medicine: Practice, Policy, Research 2
...
...
...
EDM Lumbar Drainage Kit with and without Bioglide are fabricated of radiopaque (barium impregnated) silicone tubing, and are packaged with stainless steel stylets inserted in the lumen....
Medicine Products: